Dunkirk, N.Y.
Athenex is planning to break ground by April of 2018 on a pharmaceutical manufacturing facility in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 320,000-sf project will include a 281,000-sf building providing manufacturing, research, office, and warehouse space. Completion is expected in 2019. A second phase of development comprising a 39,000-sf expansion is slated for occupancy in 2020. The general contractor for the project is M+W Group and the estimated cost of construction is $210 million.
